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Abstract 
Background: Multiple sclerosis (MS) is an autoimmune, neuroinflammatory disease, with an unclear etiology. How‑
ever, T cells play a central role in the pathogenesis by crossing the blood–brain‑barrier, leading to inflammation of the 
central nervous system and demyelination of the protective sheath surrounding the nerve fibers. MS has a complex 
inheritance pattern, and several studies indicate that gene interactions with environmental factors contribute to 
disease onset.
Methods: In the current study, we evaluated T cell dysregulation at the protein level using electrospray liquid chro‑
matography–tandem mass spectrometry to get novel insights into immune‑cell processes in MS. We have analyzed 
the proteomic profiles of  CD4+ and  CD8+ T cells purified from whole blood from 13 newly diagnosed, treatment‑
naive female patients with relapsing–remitting MS and 14 age‑ and sex‑matched healthy controls.
Results: An overall higher protein abundance was observed in both  CD4+ and  CD8+ T cells from MS patients when 
compared to healthy controls. The differentially expressed proteins were enriched for T‑cell specific activation path‑
ways, especially CTLA4 and CD28 signaling in  CD4+ T cells. When selectively analyzing proteins expressed from the 
genes most proximal to > 200 non‑HLA MS susceptibility polymorphisms, we observed differential expression of eight 
proteins in T cells between MS patients and healthy controls, and there was a correlation between the genotype at 
three MS genetic risk loci and protein expressed from proximal genes.
Conclusion: Our study provides evidence for proteomic differences in T cells from relapsing–remitting MS patients 
compared to healthy controls and also identifies dysregulation of proteins encoded from MS susceptibility genes.
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Background
Multiple sclerosis (MS) typically affects young adults and 
is the most common non-traumatic cause of neurologi-
cal impairment. It affects around 2.5 million individuals 
worldwide leading to both physical and cognitive deficits 
[1]. MS is a chronic inflammatory, demyelinating disorder 
of the central nervous system (CNS) where lymphocyte-
mediated inflammation causes demyelination and axonal 
degeneration. The underlying pathogenesis remains 
partly unclear, but T lymphocytes, both  CD4+ and  CD8+ 
T cells, have long been considered to play pivotal roles 
in MS pathogenesis [2, 3]. Also, the genetic architecture 
of MS susceptibility, emerging from genome-wide asso-
ciation studies, indicates an important role for the adap-
tive immune system, in particular T cells for MS-disease 
onset [4, 5].
Studies of MS etiology in monozygotic twins and 
recurrence risk in siblings indicate that MS has a com-
plex inheritance pattern [6]. Furthermore, parent-of-
origin effects affect inheritance of MS in rodents, and 
several studies indicate that gene-environment interac-
tions contribute to MS development. Altogether, this 
suggests that also epigenetic mechanisms play a role in 
MS etiology [7]. Both genome-wide studies on epige-
netic modifications, such as DNA methylation, as well as 
transcriptomic analyses in immune cells have been con-
ducted in order to investigate the potential dysregulation 
of immune cells in MS. Epigenetic profiling in peripheral 
blood mononuclear cells and in immune cell subtypes, 
i.e.  CD4+ and  CD8+ T cells, suggests global differences 
in DNA methylation between MS patients and healthy 
controls [8–12]. Of note, a few single genes displayed sig-
nificant differential DNA methylation levels between MS 
patients and healthy controls, but no overlap, except for 
in the HLA-DRB1 locus [12, 13], was observed between 
the different studies [7]. Microarray analyses of blood 
from MS patients and healthy controls indicate dysreg-
ulation of T cell pathways during MS pathogenesis [14, 
15]. Recent candidate-gene approaches have profiled 
transcriptional changes in T cells from MS cases and 
healthy controls, and identified dysregulation of several 
genes, e.g. MIR-21 and corresponding target genes [16] 
and THEMIS [17]. However, the correlation between 
mRNA and protein copy numbers varies widely [18, 19]. 
Therefore, performing quantitative high-resolution mass 
spectrometry-based proteomics gives a unique opportu-
nity for system-wide studies at the protein level.
Since the 1970′ies, HLA-DRB1*15:01 has been estab-
lished as the major genetic risk factor in MS [6]. Recent 
genome-wide screenings have however identified more 
than 200 non-HLA single nucleotide polymorphisms 
(SNPs) associated with MS risk [4, 5, 20]. The majority of 
the non-HLA MS associated SNPs are non-coding, and 
an enrichment of these variants is observed in regulatory 
regions of DNA (DNase hypersensitive sites) in immune 
cells from the adaptive arm of the immune system, i.e. B 
and T cells [21]. In addition, given the widespread pres-
ence of expression quantitative trait loci (eQTLs) in the 
genome [22], it is likely that a number of MS-associated 
SNPs or SNPs inherited together with the MS-associ-
ated SNPs might act as eQTLs in immune cells. Indeed, 
a recent study identified 35 significant eQTLs from 110 
non-HLA MS-associated SNPs in peripheral blood mon-
onuclear cells from MS patients [23]. However, whether 
these expression differences at the transcriptomic levels 
also persists to the protein level is currently unknown.
The overall objective for this project is to evaluate 
immune dysregulation at the protein level in MS using 
liquid chromatography combined with mass spectrom-
etry. We analyzed the proteomic profile of purified 
immune-cell subsets, i.e.  CD4+ and  CD8+ T cells, from 
genotyped relapsing–remitting MS (RRMS) patients and 
healthy controls, which allows us to disentangle poten-
tial cell-subtype specific differences that could not be 
detected in a heterogeneous cell material, permitting a 
comprehensive understanding of disease mechanisms 
of MS. Correlating protein expression with genotypes of 
MS-associated SNPs allowed for identification of protein 
expression quantitative trait loci (pQTLs).
Methods
MS patients and healthy controls
Samples from 13 untreated, female Norwegian MS 
patients with RRMS and 14 age-matched, female Nor-
wegian healthy controls were included (see Table  1 for 
demographic, clinical and biochemical information). 
For two of the patients, the EDSS score was assessed by 
inspection of their medical journals. All patients and 
healthy controls were self-declared of Nordic ancestry. 
Patients were recruited from the MS out-patient clinic 
at the Oslo University Hospital, Oslo, Norway and the 
healthy controls among hospital employees. All MS 
patients fulfilled the updated McDonald criteria for MS 
[24], did not have an ongoing infection and had not expe-
rienced a relapse or received steroids in the 3 months 
prior to enrollment. The diagnosis was set less than 1 
year prior to inclusion in the study. The healthy controls 
did report to have no MS in near family.
DNA isolation and genotyping
DNA was purified from blood (DNeasy Blood & Tissues 
Kit, Qiagen, Redwood City, CA, USA). Samples were 
genotyped with the Human Omni Express BeadChip 
(Illumina, San Diego, CA, USA).
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Isolation of human  CD4+ and  CD8+ T cells, sample 
preparation and protein digestion
Peripheral blood mononuclear cells were isolated from 
whole blood by Lymphoprep (Axis Shield, Dundee, 
Scotland), before positive selection of  CD8+ T cells 
(EasySep™ Human  CD8+ Selection Kit, STEMCELL 
Technologies, Vancouver, Canada) followed by nega-
tive selection of  CD4+ T cells (EasySep™ Human 
 CD4+ T cell Isolation kit, STEMCELL Technologies). 
Cells that achieved cell purity of more than 95% as 
measured by flow cytometry (Attune Acoustic Focus-
ing Flow Cytometer, Life Technologies, Carlsbad, CA, 
USA) were included in the study. Two  CD8+ T cell 
samples from MS patients did not reach 95% cell purity 
and were excluded from the analyses. Antibodies used 
for flow cytometry analyses were fluorescein isothi-
ocyanate-conjugated mouse anti-human CD4 (clone 
RTF-4 g, Southern Biotech, Birmingham, AL, USA), 
mouse anti-human CD8 (clone HIT8a, BD biosciences, 
San Jose, CA, USA) and mouse IgG1 isotype control 
(15H6, Southern Biotech).
Sample preparation and protein digestion
The pellet of 1 × 106 cells from each sample was kept 
until use at − 80 °C. The pellets were then solubilized in 
100  μl 0.1  M Tris–HCl pH 7.6 containing 4% SDS and 
homogenized at room temperature by sonication 3–4 
times at 30% amplitude for 30 s with an ultrasonic pro-
cessor with thumb-petuated pulser (Vibra-cell VC130 PB 
from Sonics and Materials Inc., Newton, CT, USA). After 
centrifugation for 10  min at 16,200 × g, supernatants 
were collected. Protein concentration in samples was 
measured by Pierce BCA protein assay (Thermo Fisher 
Scientific, Rockford, IL, USA) and the absorbance values 
at 562 nm were read on Multiskan FC 3.1 ELISA reader 
(Thermo Fisher Scientific). To 40  μl supernatant cor-
responding to about 10  μg protein, 4  μl 1  M DTT was 
added for reduction and incubated at 95  °C for 5  min. 
After cooling, SDS removal by dilution with urea and 
cysteine alkylation, digestion of proteins were accom-
plished using the filter aided sample preparation (FASP) 
protocol [25]. On the  MicroconR-30 centrifugal filters 
(Merck Millipore Ltd, Ireland), proteins were digested 
Table 1 Characteristics of individual MS patients and summaries of patients and healthy controls
The table includes data for each individual MS patient at inclusion, from the left: patient identity number;  
aage category; number of years since first MS symptoms; EDSS; MSSS; presence of OCB in the cerebrospinal fluid; bMRI lesion categories; presence of contrast 
enhancing lesions (MRI); symptoms at onset and family history of MS. Below follows summary statistics with mean (range) for age category, years since first symptoms 
and MSSS and median (range) labelled with * for EDSS and MRI lesion categories
EDSS expanded disability status scale, MSSS MS severity score, OCB oligoclonal bands, MRI magnetic resonance imaging, N/A not applicable
a Age category: 1 = 25–29 years; 2 = 30–34 years; 3 = 35–39 years; 4 = 40–44 years; 5 = 45–49 years; 6 = 50–54 years
b MRI lesion categories:: 1 = 0–10 lesions; 2 = 10–20 lesions; 3 = more than 20 lesions
Patient Age  categorya Years 
since first MS 
symtoms





Symptoms at onset Family 
history 
of MS
MS1 3 6 2.5 7.1 Yes 3 Yes Visual No
MS2 1 4 1 2.44 Yes 2 Yes Brainstem Yes
MS3 6 7 3 7.93 Yes 1 No Visual Yes
MS4 1 0.75 1.5 4.3 Yes 1 Yes Sensory No
MS5 1 15 3.5 8.64 Yes 1 No Sensory No
MS6 4 0.75 2 5.87 Yes 3 Yes Brainstem No
MS7 2 0.5 1 2.44 Yes 3 No Sensory No
MS8 4 2 1 2.44 Yes 3 Yes Visual Yes
MS9 5 3 2.5 7.08 No 3 Yes Sensory, bladder/
bowel
No
MS10 1 0.75 3 7.93 Yes 1 Yes Pyramidal Yes
MS11 6 19 1.5 4.3 Yes 1 No Sensory No
MS12 5 14 2.5 7.08 Yes 2 No Visual No
MS13 1 1 1.5 4.3 Yes 2 Yes Sensory No
Summarized
Patients mean or 
median* (range)
37.2 (25–52) 5.7 (0.75–19) 2 (1–3.5)* 5.5 (2.4–8.6) N/A 2* N/A N/A N/A
Healthy controls 
mean (range)
32.6 (23–47) N/A N/A N/A N/A N/A N/A N/A N/A
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with a protein-to-trypsin ratio of 50:1 (sequencing grade-
modified trypsin from Promega, GmbH, Mannheim, 
Germany) [26]. After incubation overnight at 37 °C, tryp-
tic peptides were collected by washing the filter three 
times with 50 mM ammonium bicarbonate pH 8.5, and 
with 0.5 M NaCl, each step followed by centrifugation at 
11,000 × g [25]. Sample cleanup was performed using a 
reverse-phase  OasisR HLB μElution Plate  30  μm (2-mg 
HLB sorbent, Waters, Milford, MA) [27]. After lyophi-
lization, the dried peptides were suspended in 12  μl of 
0.1% formic acid containing 2% acetonitrile. 2  μl were 
used for protein quantification based on absorbance at 
280 nm using a NanoDrop spectrophotometer (Thermo 
Fisher Scientific). The sample volume was adjusted to 
1 μg/μl and approximately 1 μg of the mixture was ana-
lyzed with mass spectrometry.
Liquid chromatography–mass spectrometry/mass 
spectrometry analysis
The peptides were analyzed by electrospray liquid chro-
matography–tandem mass spectrometry (LC–MS/MS) 
using a linear ion trap–orbitrap instrument (Orbitrap 
Elite, Thermo Fisher Scientific). The LC run length of 3 
h was performed on a 50 cm analytical column (Acclaim 
PepMap 100, 50  cm × 75  µm ID nanoViper column, 
packed with 3 µm C18 beads (Thermo Fisher Scientific)). 
Peptides were loaded and desalted on a pre-column 
(Acclaim PepMap 100, 2 cm × 75 µm ID nanoViper col-
umn, packed with 3 µm C18 beads (Thermo Fisher Scien-
tific)) with 0.1% (v/v) trifluoroacetic acid, and eluted with 
a gradient composition as follows: 5% B during trapping 
(5 min) followed by 5–7% B over 1 min, 7–32% B for the 
next 129 min, 32–40% B over 10 min, and 40–90% B over 
5  min. Elution of very hydrophobic peptides and con-
ditioning of the column were performed during 20  min 
isocratic elution with 90% B and 20  min isocratic elu-
tion with 5% B respectively. Mobile phases A and B with 
0.1% formic acid (vol/vol) in water and 100% acetonitrile 
respectively, and the flow rate was of 270 nl per min. A 
full scan in the mass area of 300–2000 Da was performed 
in the Orbitrap. For each full scan performed at a resolu-
tion of 240,000, the 12 most intense ions were selected 
for collision induced dissociation (CID). The settings of 
the CID were as following: threshold for ion selection 
was 3000 counts, the target of ions used for CID was 1e4, 
activation time was 10  ms, isolation window was 2  Da, 
and normalized collision energy was 35 eV.
Mass spectrometry data analysis
MS raw files were analyzed by the MaxQuant soft-
ware [28] (version 1.5.6.0), and peak lists were searched 
against the human SwissProt FASTA database (version 
May 2017), and a common contaminants database by 
the Andromeda search engine. As variable modification, 
methionine oxidation was used and as fixed modification 
cysteine carbamidomethylation was used. False discov-
ery rate was set to 0.01 for proteins and peptides (mini-
mum length of six amino acids) and was determined by 
searching a reverse database. Trypsin was set as digestion 
protease, and a maximum of two missed cleavages were 
allowed in the database search. Peptide identification 
was performed with an allowed MS mass deviation toler-
ance of 20 ppm, and MS/MS fragment ions could deviate 
by up to 0.5  Da. For accurate intensity-based label-free 
quantification in MaxQuant [MaxLFQ [29]], the type of 
label was “1″ for LFQ with a minimum ratio count of “2″. 
For matching between runs, the retention time alignment 
window was set to 20  min and the match time window 
was 0.7 min.
Statistical analyses
The statistical significance between comparisons was 
evaluated using a two-tailed Student t test, p < 0.05 was 
considered significant. The equality of variances of 
patient and control distributions was assessed with an 
F-test. Consequently, a Student t test with unequal vari-
ances was used when the F-test was significant (p < 0.05) 
and with equal variances otherwise. Area under the ROC 
curve (AUC) analyses of all significantly expressed pro-
teins (p < 0.05) was calculated using GraphPad Prism 6 
(La Jolla, CA, USA). Individual scatter plots of selected 
proteins (Figs. 4, 5) was created using GraphPad Prism 6. 
For the genotype-wise comparisons, a Students unpaired 
t-test with equal variances was performed when the data 
were normally distributed, if not, the non-parametric 
Mann U Whitney test was performed (GraphPad Prism 
6).
Data processing, principal component and hierarchical 
clustering analyses
Proteins identified as “only identified by site”, “reverse” 
or “potential contaminant” by Max Quant were removed 
from further analyses. In Perseus (Perseus Software, ver-
sion 1.6.0.7), the normalized LFQ intensities from Max 
Quant were log2 transformed and the normal distribu-
tions were controlled using histogram function for each 
individual. Proteins with at least 70 percentage valid val-
ues in each group (healthy control and MS) were ana-
lyzed. Further, hierarchical clustering was performed 
using Z-scores created by default settings in Perseus. A 
principal component analysis (PCA) plot was generated 
using protein intensities as variables, with the missing 
protein intensity values imputed from the normal distri-
bution using default settings in Perseus.
Page 5 of 18Berge et al. Clin Proteom           (2019) 16:19 
Ingenuity pathway analyses
QIAGEN’s  Ingenuity® pathway Analysis  (IPA®, QIA-
GEN, version 44691306 date; 2018-06-15, build version: 
481437M date; 2018-08-25) was used for functional 
interpretation of significantly regulated proteins. The 
default settings were used, except only the following 
confidence, species and tissues and cells were permitted: 
“only experimentally observed” (confidence), “only mam-
mals” (species) and “only T cells” (primary and cell-lines 
(tissues and cells)). A Benjamin-Hochberg (B-H) multiple 
testing correction was used, where a −log(B-H p-value) 
of 1.3 was considered as significant.
Results
Differential protein expression is observed in T cells 
between MS patients and healthy control
In this study, we monitored the difference in the prot-
eomic profiles in T cells, i.e.  CD4+ and  CD8+ T cells, 
between RRMS patients (n = 13) and healthy controls 
(n = 14) in a label-free manner. We were able to identify 
and quantify 2031 and 2259 proteins in  CD4+ and  CD8+ 
T cells, respectively. In  CD4+ T cells, 228 proteins were 
differentially expressed (p < 0.05) between MS cases and 
healthy controls (listed in Additional file  1: Table  S1), 
whereas 195 proteins were differentially expressed 
between the two groups in  CD8+ T cells (listed in Addi-
tional file 2: Table S2). Of the differentially expressed pro-
teins, 74% in  CD4+ T cells and 64% in  CD8+ T cells were 
more abundant in samples from MS patients compared 
to healthy controls. The separation of MS versus healthy 
controls based on these proteins is shown in the principal 
component analyses (PCA) plot in Fig. 1, where the first 
component captures 55%  (CD4+) and 62%  (CD8+) of the 
variance, whereas the second component captures 11% 
 (CD4+) and 9%  (CD8+). Of the differentially expressed 
proteins, 26 overlapped between  CD4+ and  CD8+ T cells.
Ingenuity pathway analyses of differentially expressed 
proteins
To increase the chance of extracting the true candidate 
proteins differentially expressed between MS cases and 
healthy controls with a potential impact on cell func-
tion, a more stringent filter for selection was applied. 
By selecting proteins that fulfilled two of the three fol-
lowing criteria within the group of significantly differ-
ential expressed proteins (p < 0.05): (1) p-value cut-off 
of p < 0.01; (2) area under the curve (AUC) > 0.8 and (3) 
log2 fold change > [0.2], we created a top-hit list of dif-
ferentially expressed proteins. Out of the 228 and 195 
proteins listed in Additional file  1: Table  S1 and Addi-
tional file  2: Table  S2 from  CD4+ and  CD8+ T cells, 
respectively, we ended up with a shorter list of 90 and 61 
proteins (Tables 2, 3), where five proteins expressed from 
the TOMM70A, ACP1, AGL, ATP2A2 and TPM4 genes 
appeared in both top-hit lists.
The ingenuity pathway analyses (IPA) software was 
used for network analyses of the top-hit proteins 
(Tables  2, 3) from the  CD4+ and  CD8+ T cell data sets 
separately. After correcting for multiple testing, we iden-
tified 14 biological processes in  CD4+ T cells that were 
affected by the presence of MS disease (Fig. 2), however, 
no pathways were significant for  CD8+ T cells. When 
performing network analyses of the entire list of 195 dif-
ferentially expressed proteins (p < 0.05) from  CD8+ T 
cells, two pathways were significant after multiple testing, 
i.e. the sirtuin signaling pathway and the protein kinase 
A pathway (data not shown). In the  CD4+ T cell data set, 
mainly T cell activation pathways, such as CTLA4, CD28, 
T cell receptor, PKCθ and iCOS-iCOSL signaling and cal-
cium-induced T lymphocyte apoptosis were identified. 
Fig. 1 Principal component analyses (PCA) of differentially expressed 
proteins. PCA of proteins significantly different (p < 0.05) in a  CD4+ 
and b  CD8+ T cells from MS cases (red) compared to healthy controls 
(blue)























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Page 13 of 18Berge et al. Clin Proteom           (2019) 16:19 
In addition, general pathways as for instance the pentose 
phosphate pathway in addition to immune related path-
ways were represented.
Hierarchical clustering
The normalized intensities of the 90 and 61 proteins in 
the top-hit list (Tables  2, 3) in  CD4+ and  CD8+ T cells 
from MS patients and healthy controls were used as 
input to hierarchical clustering in Perseus (Fig.  3). The 
proteomic profiles for each cell type were divided into 
two groups consisting mainly of (1) MS and (2) healthy 
control samples. The differentially expressed proteins are 
divided into two major groups that are oppositely regu-
lated between MS patients and healthy controls. Using 
IPA, we did not detect any enrichment for specific biolog-
ical pathways if we separately analyzed proteins that are 
either up- or down-regulated in  CD8+ T cells from MS 
patients. However, in the proteins that are upregulated in 
MS  CD4+ T cells, there is an enrichment for T cell spe-
cific activation pathways, in addition to general pathways 
such as the pentose phosphate and sirtuin pathways. For 
the proteins that are down-regulated in MS  CD4+ T cell 
samples, network analyses in IPA showed enrichment 
of proteins in integrin signaling and endocytic pathways 
(data not shown). Of note, we observed three excep-
tions where two MS patients clustered together with the 
healthy controls (one for each data set) and one healthy 
control clustered with MS patients in the  CD8+ T cell 
data set.
Analyses of proteins expressed by MS susceptibility genes
To date more than 200 non-HLA associated MS risk 
SNPs have been identified by genome-wide approaches 
[4, 5, 20]. We next selectively analyzed the abundance 
of proteins expressed from the gene(s) most proximal 
to these MS-associated SNPs in order to identify pro-
teins with a potential impact on MS disease. For inter-
genic MS-associated SNPs, we analyzed the abundance 
of the proteins expressed from the most proximal gene 
both upstream and downstream of the SNPs. Not all 
MS susceptibility genes are expressed in T cells, and in 
our samples, we detected 31 proteins encoded from MS 
susceptibility genes in  CD4+ T cells and 37 proteins in 
 CD8+ T cells. Of these, eight proteins (seven in  CD4+ T 
and one in  CD8+ T cells) were differentially expressed in 
samples from MS cases versus healthy controls (Fig. 4).
To assess the functional link between GWAS-identified 
risk variants and disease, we evaluated whether there was 
any correlation between MS risk genotypes and expres-
sion of proteins encoded from the most proximal gene(s). 
For proteins that did not display any difference in abun-
dance in samples from MS cases and healthy controls, 
i.e. 24 and 36 proteins from  CD4+ and  CD8+ T cells, 
respectively, samples (from both MS patients and healthy 
controls) were pooled by carriers of the risk allele at each 
Fig. 2 Enriched pathways in  CD4+ T cells from MS patients. The graph displays the cellular pathways enriched in the proteomic profiles of the 
top‑hit regulated proteins from MS patients as compared with healthy controls in  CD4+ T cells after correcting for multiple testing (p‑value, left 
axis). The orange line represents the ratio of the number of proteins in the data set of differentially expressed proteins divided by the number of 
proteins in the reference data set for that specific pathway (right axis)
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SNP as compared to samples from individuals homozy-
gous for the protective allele for each SNP. We observed 
a genotype-dependent expression of proteins expressed 
from the STAT3 and LEF1 genes in  CD4+ T cells and 
the RUNX3 gene in  CD8+ T cells (Fig. 5). However, after 
multiple testing these correlations did not reach statisti-
cal significance.
Discussion
MS is considered as an autoimmune disorder of the CNS 
and the pathological immune dysregulation involves an 
interaction between the innate and adaptive immune 
system. T cells are thought to be one of the main cellu-
lar drivers for disease development, and from genome-
wide association screens, a significant enrichment of 
genetic loci encoding proteins in T-cell specific pathways 
is observed [5]. Nevertheless functional and epigenomic 
annotation studies of genetic risk loci suggests that also 
other cells of the immune system are involved [5, 21, 30]. 
Proteomic profiling of whole blood or peripheral blood 
mononuclear cells could contribute to achieve mecha-
nistic insights behind the development of MS pathology. 
However, such samples are heterogeneous in their cel-
lular composition, so any cell-specific variation may be 
overshadowed by variation in the proportions of the vari-
ous cell types. In the current study, we therefore purified 
 CD4+ and  CD8+ T cells and compared their respective 
proteomic profiles between RRMS patients and healthy 
controls using liquid chromatography–tandem mass 
spectrometry. Our study provides evidence for proteomic 
Fig. 3 Hierarchical clustering of differentially expressed proteins. The heatmaps show the hierarchical clustering of differentially expressed proteins 
from the top‑hit list fulfilling two out of the three criteria: p < 0.01, AUC > 0.8 and log fold change > [0.2] in a  CD4+ T cells and b  CD8+ T cells from MS 
patients and healthy control using Perseus. Red: upregulated in MS samples, green: down‑regulated in MS samples, grey: missing values. MS (black): 
samples from MS patients; HC (blue): samples from healthy controls
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differences in T cells from RRMS patients compared to 
healthy controls and identifies three putative pQTLs for 
proteins encoded by three MS susceptibility genes.
MS is an inflammatory disease that affects the CNS. 
The cerebrospinal fluid is an obvious fluid to perform 
proteomic profiling into search for biomarkers of MS, 
as it reflects ongoing pathological and inflammatory 
processes in the CNS. However, in the current study, 
we are examining immune cell subsets, i.e.  CD4+ and 
 CD8+ T cells that enables us to identify proteins and 
pathways involved in MS development. We are aware 
of that also other cells of the immune system, including 
B cells and innate cells such as NK cells and dendritic 
cells in addition to brain-resident immune cells, i.e. 
astrocytes [20], have potential impact on MS pathogen-
esis. However, this study enables us to achieve mecha-
nistic insights into T-cell mediated pathology of MS. 
Identification of novel proteins and pathways involved 
Fig. 4 Differential expression of proteins encoded by MS susceptibility genes. The scatter plots represent the log2‑transformed protein abundances 
of proteins expressed from indicated MS susceptibility genes in  CD4+ T cells and  CD8+ T cells from MS patients (MS) and healthy controls (HC). 
Student t tests were used to compare the groups as specified in Materials and Methods. The horizontal lines represents the median within the 
groups
Fig. 5 Genotype‑dependent expression of proteins encoded by MS susceptibility genes. The scatter plots display the log2‑transformed protein 
abundances of proteins expressed from indicated MS susceptibility genes as function of the MS risk SNP genotype in samples from  CD4+ T cells (left 
and middle plot) and  CD8+ T cells (right plot) from both MS patients and healthy controls sorted for the genotype of indicated MS‑susceptibility 
SNPs. For normalized distributions (LEF1 and RUNX3), Student t‑test were performed, otherwise (STAT3), the non‑parametric Mann U Whitney test 
was performed to compare the groups. The horizontal lines represents the median within the groups
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in MS pathology could enable progress in the develop-
ment of new drug targets in order to improve the clini-
cal outcome of MS.
Hierarchical clustering of the differentially expressed 
proteins from our top-hit list of 90 and 61 proteins from 
 CD4+ and  CD8+ T cells, respectively, divided the sam-
ples into two main groups with MS patients and healthy 
controls. Of note, for each of the cell types, there was one 
MS patient sample (not the same in the two cell types) 
clustering with the healthy control group. One of these 
patients (MS12) has a benign form of MS, and in con-
trast to all other patients, this patient is currently elec-
tively untreated (3 years after inclusion to the study). 
One healthy control also groups with the MS patients for 
 CD8+ T cells; however, whether this control experienced 
an undetected inflammatory condition or have developed 
autoimmunity after sample collection giving rise to a pro-
teomic profile similar to MS cases is not known. Even 
though we have separated immune-cell subsets from the 
entire pool of immune cells in blood, we acknowledge 
that these sub-populations can be divided further into 
different subpopulations such as Th1 and Th2 cells, effec-
tor, memory and regulatory T cells. Whether the individ-
uals not clustering with their own group have differences 
in the proportion of  CD4+ and  CD8+ T cell subsets is not 
known and could potentially affect the proteomic profile 
achieved. The fold change in protein abundance in T cells 
from MS patients and healthy controls are modest. How-
ever, enrichment in specific pathways (see Fig. 2) suggests 
that they collectively may have an impact on selected 
T cell responses. Also, the study is limited by the small 
sample size, and further studies are needed to validate 
and verify the biological impact of selected proteins in T 
cells.
Of the top-ten (based on p-value) differentially 
expressed proteins in each cell type, only three of them 
have previously been identified to have a potential role 
for MS, either through a genetic association, i.e. Lck 
[20], as a biomarker for MS progression and severity, i.e. 
macrophage migration inhibitory factor (MIF) [31, 32] 
or in functional studies, where gasdermin-D (GSDMD) 
is shown to promote inflammatory demyelination both 
in human cells and in murine models [33]. Of note, a 
selection of the top hit proteins in T cells [TAR binding 
protein (TARDBP), calnexin (CANX) and AP2 associ-
ated kinase 1 (AAK1)] have been shown to play impor-
tant roles for other neurodegenerative disorders such as 
Alzheimer’s disease, Parkinson’s disease and amyotrophic 
lateral sclerosis [34–37], suggesting common disease 
mechanisms across neurodegenerative disorders and 
highlighting the importance for these proteins also in 
immune cells.
MS is an inflammatory disease, and therefore it is 
no surprise that the differentially expressed proteins 
in  CD4+ T cells are enriched for pathways related to 
T cell activation or immune function. Whether these 
pathways are affected because of the active inflamma-
tion that is characteristic for the early phase of RRMS 
or whether similar changes can be detected prior to 
disease onset is not known. MS develops in genetic 
susceptible individuals, and genome-wide screenings 
have highlighted the importance of genes involved 
in T cell differentiation, in  CD4+ T cells in particu-
lar [5]. Interestingly, we have identified eight proteins 
encoded by MS susceptibility genes (LCK, GRAP2, 
CD5, ZC3HAV1, SAE1, EPPK1 and CD6 in  CD4+ T 
cells and TNFAIP8 in  CD8+ T cells), which are more 
abundant in T cells from MS patients compared to 
healthy controls. This underlines the potential role 
for these MS susceptibility genes in T cells during MS 
development prior to disease onset.
Furthermore, correlating MS risk genotype with pro-
tein expression from genes proximal to MS risk SNPs, 
we identified three potential pQTLs, i.e. rs1026916, 
rs9992731 and rs6672420. Samples from individuals 
homozygous for the protective allele displayed higher 
expression of the specified proteins compared to sam-
ples from individual being a carrier of the risk allele. 
Even though these correlations did not reach statistical 
significance after multiple testing, the data indicate that 
these SNP-protein pairs are of relevance to study further 
as the corresponding MS associated SNPs could act as 
pQTLs. Interestingly, the rs1026916 SNP has previously 
been shown to act as an eQTL for STAT3 (at the mRNA 
level) in skeletal muscle and tibial artery [38]. Rs1026916 
lies within a region with moderately high histone H3 
acetylation levels, but outside DNAse clusters and tran-
scription factor binding sites [39]. Whether this SNP 
affects transcription factor binding and thereby regulates 
transcription remains to be analyzed. Our study further 
suggests a functional implication of this SNP or a SNP 
tagged by rs1026916 in T cells. Neither rs6672420 nor 
rs9992731 are reported to act as an eQTLs [38]. How-
ever, the correlation between mRNA and protein copy 
numbers can vary widely [18, 19] and this study sug-
gests that these SNPs could act as pQTLs in T cells. In 
contrast to rs9992731 that is not situated in any typical 
gene-regulatory region, in silico analyses suggests that 
rs6672420 might affect gene expression, as it is located 
in a region shown by chromatin immunoprecipitation 
to be bound by RNA polymerase 2 (POLR2A) and the 
STAT5A transcription factor [39]. Confirmatory stud-
ies in T cells need to be pursued in order to confirm the 
relationship between genotype at rs6672420, transcrip-
tion factor occupancy and gene and protein expression 
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of RUNX3. Altogether, the reported pQTLs suggests fur-
ther exploration of LEF1, STAT3 and RUNX3 to under-
stand the molecular pathways involved in disease with 
the ultimate goal to identify new therapeutic targets.
Conclusion
We show that there is a dysregulation at the protein level 
in T cells from RRMS patients at an early stage of disease. 
Pathway analyses, pinpoints to the importance of  CD4+ 
T-cell specific activation pathway, which is indicative of 
an inflammatory condition. By specifically analyzing pro-
teins expressed from MS susceptibility genes, eight pro-
teins were found to be dysregulated in T cells from MS 
patients. In addition, we identified three novel pQTLs, 
which might contribute to mechanistically understand 
the molecular background of MS development and the 
biology behind three SNPs that have been identified as 
MS susceptibility gene variants through genome-wide 
screenings.
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